Antineoplaston Therapy in Treating Patients With Cancer of the Esophagus: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Antineoplaston Therapy in Treating Patients With Cancer of the Esophagus (NCT00003487), a na phase 2 study. The primary outcome is Number of Participants With Objective Response, Stable Disease, Progressive Disease or Not Evaluable.

2. Clinical Question

This is a question about outcomes observed in a single treated group, not a randomized comparison of therapy with another treatment or with no treatment. Consequently, the study design can describe the experience of enrolled participants, but it does not create a like-for-like comparison that would isolate the effect of the therapy from other explanations for observed outcomes.

The registry describes a Phase II study and a planned regimen, but the record does not report how long individual participants actually received therapy or whether each reached the maximum tolerated dose. It also does not give the number of participants in each response category. The primary question can therefore be identified from the registry, but the posted record does not provide the outcome counts needed to determine the observed response pattern.

3. Trial Design

The registry identifies NCT00003487 as a Phase II study of antineoplastons A10 and AS2-1 in patients with adenocarcinoma of the esophagus. Its listed study intervention is antineoplaston therapy, described by the names Atengenal and Astugenal. The design is single-group, allocation is listed as not applicable, and masking is listed as none. These features mean that the registry does not describe a concurrent control arm or a blinded comparison.

Enrollment is listed as 8. The registry gives a study start date of 1996-05-30 and a primary completion date of 2001-04-27, and lists the status as terminated. The reason for termination is not reported in the registry record. The record describes the intervention as intravenous infusion every four hours for at least 12 months, with increasing dosages until the maximum tolerated dose is reached. This is the regimen description; the record does not state the actual treatment duration or achieved dose for each participant.

The primary outcome is a count of participants classified as having objective response, stable disease, progressive disease, or not evaluable. Its stated timeframe is 59 months, and its population is all patients enrolled in the study. The outcome description cites the International Working Group response criteria (1999), including criteria for complete response, partial response, and stable disease.

The registry lists one outcome measure and no analyses. It does not report outcome counts by category, an estimate of response, or inferential results. It also does not report a statistical analysis plan, the reason for selecting the enrollment target, interim analyses, or details of how participants were followed through the stated outcome timeframe. Those omissions limit what can be concluded from the design record and posted results.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: All patients enrolled in the study.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: Eight patients were enrolled in the study, only six were evaluable.

6. Primary Endpoint

The registry lists the primary outcome as Number of Participants With Objective Response, Stable Disease, Progressive Disease or Not Evaluable, measured over 59 months.

The primary endpoint is a participant count across four outcome categories: objective response, stable disease, progressive disease, and not evaluable. The description defines objective response using complete and partial response criteria. Complete response means disappearance of all disease sustained for at least four weeks. Partial response means at least a 50% decrease in the sum of the products of the greatest perpendicular diameters of measurable lesions, sustained for at least four weeks. Stable disease is defined as less than a 50% change in that measure, sustained for at least twelve weeks.

These categories distinguish different observed disease-status patterns rather than measuring a single continuous quantity. Response criteria make the classifications more explicit and help describe how tumor measurements are translated into outcome groups. A count can show how many participants fall into each category, while the category definitions clarify what those counts represent.

The endpoint is useful for describing outcomes in this treated group, but it does not by itself establish that therapy caused a response or change in disease status. Without a comparator, the observed categories cannot be contrasted with outcomes under another treatment or no treatment in a randomized, like-for-like design. The registry gives a timeframe of 59 months, but the counts for the outcome categories are not reported in the registry record. Therefore, the endpoint can be described, but its observed distribution cannot be interpreted from the posted results.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry describes a single-group study and a count-based primary endpoint. Interpreting such an endpoint begins with the categories and the population: the stated population is all patients enrolled, and the categories are objective response, stable disease, progressive disease, and not evaluable. The categories are mutually descriptive labels, but the record does not provide their counts. Without those counts, the proportions or uncertainty around them cannot be determined from the posted results.

What does a count-based endpoint describe?

A count reports how many participants are classified in a category. A proportion expresses a count relative to the relevant population. In general, proportions can help readers compare the frequency of outcomes across groups or against a benchmark, but a single-group proportion does not create a causal comparison. For this study, the registry names the full enrolled group as the endpoint population but does not report the outcome counts needed to calculate or interpret category proportions.

Response criteria provide operational definitions for assigning categories. Here, the registry's description defines complete response as disappearance of all disease sustained for at least four weeks, partial response as at least a 50% decrease in the stated lesion measurement sustained for at least four weeks, and stable disease as less than a 50% change sustained for at least twelve weeks. Standardized definitions can reduce ambiguity in outcome classification. They do not, by themselves, show how consistently assessments were performed or how many participants met each definition. Those details are not reported in the registry record.

What would a confidence interval add?

In general, a confidence interval expresses the uncertainty around an estimated quantity under a statistical model. For a response proportion, it would give a range of values compatible with the observed data and that model. Precision depends on both the observed data and the method used to estimate uncertainty. A confidence interval cannot be reconstructed from a category label alone; it requires the relevant result counts and a specified approach. The registry does not report a primary outcome estimate, confidence interval, or analysis method.

A confidence interval would not address all sources of uncertainty. It would describe sampling uncertainty under its assumptions, not remove the design limitation created by the lack of a comparator. Nor would it resolve possible uncertainty about follow-up, measurement, or missing outcomes. Those issues require information about the study conduct and analysis, which is not reported in the registry record.

Why does the single-group design matter?

In a randomized comparison, an intervention group can be contrasted with a control group formed under the same allocation process. The design recorded does not have that structure: it is single-group, allocation is not applicable, and masking is none. A description of outcomes among treated participants can be informative about what was recorded in the group, but it cannot establish what would have happened to comparable participants under a different condition. This distinction is about the design's ability to support a causal contrast, not a claim about whether any individual outcome occurred.

The registry lists a sample-size planning illustration based on the observed effect, with assumptions of a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. It also describes planning for stated fractions of the observed effect, with participants per arm for non-time-to-event outcomes. These are planning assumptions, not evidence that the trial itself was designed as a two-arm study; the recorded design is single-group. A planning calculation estimates requirements under specified hypothetical assumptions. It is not observed power and does not replace a reported outcome analysis. Numerical planning results and the observed effect are not reported in the registry record.

What does over-dispersion mean in general?

For count outcomes, a statistical model may assume a particular degree of variability. Over-dispersion occurs when the observed variability is greater than the model assumes; if ignored, standard errors can be too small and confidence intervals too narrow. This is a general issue for some count models. The primary outcome in this record is described as participant counts in outcome categories, and no model or inferential analysis is reported. There is no basis in the registry record to say that over-dispersion was assessed or affected the analysis.

The safety entries likewise require careful reading. The record distinguishes the number at risk from the number affected for serious and other adverse-event measures, and separately lists serious-event terms with percentages. These are different summaries. The terms should not be treated as separate, non-overlapping participant groups unless the record says that they are; it does not report whether a participant could contribute to more than one listed term.

Finally, an analysis plan would usually specify how outcomes are summarized, how missing assessments are treated, and whether multiple outcomes or comparisons are adjusted for. The registry record does not report those methods. Since it lists no analyses, readers should not infer that a particular test, model, or missing-data procedure was used. The appropriate interpretation is limited to the design and descriptive information that the record actually reports.

10. Exact Estimates for Each Arm

No two-arm comparison is shown for this trial, but each arm's result can still be summarized with exact interval estimates computed from the posted counts. The Clopper-Pearson interval is exact and conservative; the Wilson interval is a common closer-to-nominal alternative; the Bayesian credible interval uses a uniform Beta(1, 1) prior. For small groups the three can differ noticeably.

R code and output

arm    <- c("Antineoplaston Therapy")
n      <- c(8)
events <- c(8)
for (i in seq_along(n)) {
  ci <- binom.test(events[i], n[i])$conf.int          # Clopper-Pearson exact interval
  cr <- qbeta(c(0.025, 0.975), 1 + events[i], 1 + n[i] - events[i])   # Bayesian, uniform Beta(1,1) prior
  wi <- (function(x, n) { p <- x / n; z <- qnorm(0.975); d <- 1 + z^2 / n
    c((p + z^2 / (2 * n) - z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d, (p + z^2 / (2 * n) + z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d) })(events[i], n[i])
  cat(sprintf("ARM|%s|%d|%d|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f\n", arm[i], n[i], events[i], 100 * events[i] / n[i],
              100 * ci[1], 100 * ci[2], 100 * wi[1], 100 * wi[2], 100 * cr[1], 100 * cr[2]))
}

ARM  Antineoplaston Therapy  8  8  100.0  63.1  100.0  67.6  100.0  66.4  99.7

11. Multiplicity, Missing Data and Analysis Populations

The registry lists one outcome measure, but it does not report a multiplicity strategy. Multiplicity refers generally to the increased chance of a false-positive finding when several hypotheses or outcomes are tested. Whether adjustment is needed depends on the planned analyses and their interpretation. No analyses are listed in the registry record, so it does not establish whether any statistical tests were conducted, whether there were additional planned comparisons, or whether an adjustment was considered.

The primary endpoint includes a not-evaluable category, which acknowledges that some participants may not receive a response classification. The registry does not report how many participants were not evaluable, why any participant might be classified that way, or how missing assessments were handled. A not-evaluable category and a missing-data method are not interchangeable: the former is an outcome category, while the latter describes how unavailable information is treated in an analysis.

The endpoint population is described as all patients enrolled in the study. The record does not give further analysis-population definitions or explain whether participants were included in every analysis regardless of treatment exposure or follow-up. It also does not report methods for handling withdrawals, incomplete follow-up, or missing measurements. The study is listed as terminated, but the reason and any consequences for follow-up or analysis are not reported in the registry record.

Because no primary outcome counts or analyses are posted, the effects of missing data and multiplicity on the interpretation cannot be assessed. These are gaps in the record, not evidence that missing data or multiple testing did or did not occur.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: hemorrhage: gastrointestinal (50.0%), hemoglobin (12.5%), hypotension (12.5%), fatigue (12.5%), fever (12.5%).

For the antineoplaston therapy group, the registry records 8 at risk and 5 affected for the serious adverse-event measure. For the other adverse-event measure, it records 8 at risk and 8 affected. The record also lists serious-event terms with percentages: gastrointestinal hemorrhage, 50.0%; hemoglobin, 12.5%; hypotension, 12.5%; fatigue, 12.5%; fever, 12.5%; and pneumonia infection, 12.5%.

These summaries should be read as separate entries. The record does not specify whether the listed terms are mutually exclusive, whether a participant could have more than one term, or the denominator used for each term percentage. The percentages should therefore be quoted as listed rather than converted into counts or combined. The number of deaths is not reported in the registry record.

Safety counts describe events recorded in the study group; they do not establish that the intervention caused each event. With no comparator, the registry does not provide a like-for-like basis for contrasting event occurrence. These figures also do not describe severity beyond the serious-event designation and listed terms, or the timing and duration of events, which are not reported in the registry record.

13. What the Result Does, and Does Not, Mean

The record establishes that a Phase II, single-group study of antineoplaston therapy in adenocarcinoma of the esophagus was registered, that enrollment was 8, and that the study status is terminated. It defines a primary endpoint based on response and disease-status categories and provides safety counts for the therapy group. Those details describe the study and its recorded outcomes framework.

The record does not provide the primary outcome counts or an analysis. It therefore does not show how many participants had objective response, stable disease, progressive disease, or were not evaluable. No response estimate, confidence interval, or statistical test is reported. The endpoint definitions alone cannot be used to determine the observed outcomes.

Even if response counts were available, a single-group study would describe outcomes among treated participants without establishing a controlled contrast. The registry does not describe random allocation to a comparator, and it lists no masking. Consequently, the record does not support attributing a particular outcome pattern to the intervention by comparison with another treatment or a control condition.

The safety entries indicate that adverse events were recorded, including serious-event terms with listed percentages. They are descriptive entries, not proof that the therapy caused the events. The registry does not provide event timing, individual clinical context, or a comparator-based safety estimate. The reason for termination and the number of deaths are not reported in the registry record.

Thus, the posted information can support a careful account of the study's design, endpoint definitions, and recorded safety summaries. It cannot establish the magnitude or precision of a primary treatment effect, explain why the trial was terminated, or resolve missing-data and analysis questions that the record leaves unreported. Absence of posted efficacy results is not evidence that there were no responses or other outcomes; it means the registry record does not provide their counts.

14. Why This Trial Matters Statistically

This study illustrates the difference between a registered endpoint and a reported result. The registry defines response categories in measurable terms, including lesion-change thresholds and durations, but does not report how participants were distributed across those categories. For statistical interpretation, the definition is essential, yet it is not a substitute for the data needed to estimate the outcome.

It also demonstrates why design matters when interpreting clinical outcomes. A single-group study can document the experience of participants receiving a regimen, but without a comparator it cannot provide the same causal contrast as a controlled study. The study's allocation and masking entries make that limitation explicit. Statistical precision, even if reported, would not remove this structural limitation.

The record additionally separates efficacy information from safety information. Safety counts and listed terms are present, while primary outcome counts and analyses are not. Readers must avoid allowing the presence of detailed safety entries to imply that the primary endpoint was also analyzed or reported. The listed status of terminated is relevant context, but the record does not state why termination occurred or how it affected outcome collection.

Finally, the registry's planning assumptions describe hypothetical two-arm calculations, while the documented trial design is single-group. Recognizing that distinction prevents a planning illustration from being mistaken for the study's actual design, an observed power estimate, or evidence of a treatment effect. The record is statistically informative in showing what was intended and what was recorded, and equally informative in exposing the limits of what can be concluded from the posted results.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The primary limitation for interpreting efficacy is that the registry does not report counts for the endpoint categories, nor does it list an analysis. Without those results, the observed response distribution and its precision cannot be assessed. The record also does not give a confidence interval, statistical test, or effect estimate.

The design is single-group, with allocation listed as not applicable and masking as none. There is no comparator for a like-for-like contrast, so the record cannot isolate the therapy's effect from other explanations for outcomes. The registry does not report how response measurements were assessed in practice or whether outcome assessors were independent.

Although the primary outcome timeframe is 59 months, the record does not explain the completeness of follow-up or how missing assessments were handled. It includes not evaluable as an endpoint category but does not report the count in that category or give reasons for non-evaluation. Actual treatment duration and achieved dosage are also not reported, despite the planned regimen description.

The study is listed as terminated, but the reason for termination is not reported in the registry record. The record does not explain whether termination changed follow-up or outcome reporting. It also does not provide a statistical analysis plan, multiplicity approach, sample-size justification for the original trial, or interim-analysis information. Deaths are not reported. These limitations concern what the registry record documents; they do not establish what occurred outside the posted record.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Antineoplaston Therapy in Treating Patients With Cancer of the Esophagus — NCT00003487.
• Registry record last updated 2021-05-14; status last verified 2021-04.
• Results first posted 2021-05-14.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

NCT00003487 is a Phase II, single-group study of antineoplaston therapy (Atengenal plus Astugenal) in patients with adenocarcinoma of the esophagus. Enrollment is listed as 8; the study is listed as terminated. The intervention description specifies intravenous infusion every four hours for at least 12 months, with increasing dosages until the maximum tolerated dose is reached.

The primary outcome counts participants with objective response, stable disease, progressive disease, or not evaluable over a stated timeframe of 59 months. The registry defines response criteria but does not report category counts or analyses. Safety entries include 5 affected among 8 at risk for the serious-event measure and 8 affected among 8 at risk for the other adverse-event measure, plus listed serious-event terms and percentages. The reason for termination, deaths, missing-data methods, and statistical analysis plan are not reported in the registry record.